Erratum: Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine (Human Psychopharmacology (2011) 26 (422-433) DOI: 10.1002/hup.1225);Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine

Human Psychopharmacology

Volumn 26, Issue 6, 2011, Pages 422-433

  McDonnell, David P ^a   Kryzhanovskaya, Ludmila A ^a   Zhao, Fangyi ^a   Detke, Holland C ^a   Feldman, Peter D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

cholesterol; glucose; olanzapine; olanzapine long acting injection; triglycerides; weight

Indexed keywords

GLUCOSE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; COMPARATIVE STUDY; CONTROLLED STUDY; DATA COLLECTION METHOD; DIABETES MELLITUS; DRUG FORMULATION; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; MALE; METABOLIC PARAMETERS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; WEIGHT CHANGE;

EID: 80052274153     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1237     Document Type: Erratum

References (42)

1. Adams CE, Awad G, Rathbone J,. et al. 2007. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2: CD000284.
2. American Diabetes Association. 2007. Diagnosis and classification of diabetes mellitus. Diabetes Care 30: S42-S47.
3. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th Edition, Washington, DC: American Psychiatric Association.
4. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, 4th Edition, Text Revision, Washington, DC: American Psychiatric Association.
5. Babiker IE,. 1987. Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. The Journal of Clinical Psychiatry 48: 94-97. (Pubitemid 17047796)
6. Brecher M, Leong RW, Stening G, et al. 2007. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. The Journal of Clinical Psychiatry 68: 597-603. (Pubitemid 46663043)
7. Breier A, Berg PH, Thakore JH, et al. 2005. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. The American Journal of Psychiatry 162: 1879-1887. (Pubitemid 41428617)
8. Chiu CC, Chen KP, Liu HC, et al. 2006. The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients. Journal of Clinical Psychopharmacology 26: 504-507.
9. Chrzanowski WK, Marcus RN, Torbeyns A, et al. 2006. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 189: 259-266. (Pubitemid 44691547)
10. Davis JM, Matalon L, Watanabe MD, et al. 1994. Depot antipsychotic drugs. Place in therapy. Drugs 47: 741-773. (Pubitemid 24151095)
11. Detke HC, McDonnell DP, Brunner E, et al. 2010. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 10: 43.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497.
13. Gharabawi GM, Gearhart NC, Lasser RA, et al. 2007. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry 6.
14. Gillings G, Koch G,. 1991. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Information Journal 25: 411-424.
15. Hill AL, Sun B, Karagianis J, et al. 2011. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry 11: 28.
16. Hoiberg MP, Nielsen B,. 2006. Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients. Nordic Journal of Psychiatry 60: 207-212. (Pubitemid 43832468)
17. Kane JM,. 2006. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. The Journal of Clinical Psychiatry 67 (suppl 5): 9-14. (Pubitemid 43837696)
18. Kane JM, Detke HC, Naber D, et al. 2010. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. The American Journal of Psychiatry 167: 181-189.
19. Kane JM, Eerdekens M, Lindenmayer JP, et al. 2003. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. The American Journal of Psychiatry 160: 1125-1132. (Pubitemid 41070972)
20. Kinon BJ, Basson BR, Gilmore JA, et al. 2001. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. The Journal of Clinical Psychiatry 62: 92-100. (Pubitemid 32199865)
21. Lauriello J, Lambert T, Andersen S, et al. 2008. An 8-week double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. The Journal of Clinical Psychiatry 69: 790-799. (Pubitemid 351838688)
22. Lean MEJ, Pajonk FG,. 2003. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 26: 1597-1605. (Pubitemid 36929197)
23. Lindenmayer JP, Czobor P, Volavka J, et al. 2003. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. The American Journal of Psychiatry 160: 290-296. (Pubitemid 41110454)
24. Luft B, Taylor D,. 2006. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opinion on Pharmacotherapy 7: 1739-1748.
25. Masand PS, Mago R,. 2005. Second-generation antipsychotics and the metabolic syndrome. Current Psychiatry Reports 7: 153-154. (Pubitemid 40916406)
26. McDonnell DP, Detke HC, Bergstrom RF, et al. 2010. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry 10: 45.
27. McEvoy JP,. 2006. Risks versus benefits of different types of long-acting injectable antipsychotics. The Journal of Clinical Psychiatry 67 (suppl 5): 15-18. (Pubitemid 43837697)
28. McQuade RD, Stock E, Marcus R, et al. 2004. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. The Journal of Clinical Psychiatry 65 suppl 18: 47-56.
29. Mukherjee S, Decina P, Bocola V, et al. 2009. Diabetes mellitus in schizophrenic patients. Comprehensive Psychiatry 37: 66-73.
30. Neovius M, Eberhard J, Lindström E, et al. 2007. Weight development in patients treated with risperidone: a 5-year naturalistic study. Acta Psychiatrica Scandinavica 115: 277-285. (Pubitemid 46425746)
31. Newcomer JW,. 2005. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (suppl 1): 1-93. (Pubitemid 40677047)
32. Nussbaum AM, Stroup TS,. 2008. Paliperidone for treatment of schizophrenia. Schizophrenia Bulletin 34: 419-422.
33. Osser DN, Najarian DM, Dufresne RL,. 1999. Olanzapine increases weight and serum triglyceride levels. The Journal of Clinical Psychiatry 60: 767-770.
34. Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. 2007. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. The Journal of Clinical Psychiatry 68: 1733-1740. (Pubitemid 350247503)
35. Peuskens J, De Hert M, Mortimer A, et al. 2007. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. International Clinical Psychopharmacology 22: 145-152. (Pubitemid 46559870)
36. Potkin SG, Gharabawi GM, Greenspan AJ, et al. 2006. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research 85: 254-265. (Pubitemid 43947539)
37. Remington G., 2007. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Current Opinion in Psychiatry 20: 131-137.
38. Rettenbacher MA, Ebenbichler C, Hofer A, et al. 2006. Early changes of plasma lipids during treatment with atypical antipsychotics. International Clinical Psychopharmacology 21: 369-372. (Pubitemid 44498279)
39. Schmauss M, Sacchetti E, Kahn JP, et al. 2007. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. International Clinical Psychopharmacology 22: 85-92.
40. Voruganti LP, Awad AG, Parker G, et al. 2007. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research 96: 146-155. (Pubitemid 47494646)
41. World Medical Association. 2000. Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. As adopted by the 18th General Assembly; Helsinki, Finland; June 1964; and amended by the 52nd General Assembly: Edinburgh, Scotland; October 2000.
42. Wu RR, Zhao JP, Liu ZN, et al. 2006. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 186: 572-578.